ARTICLE | Politics & Policy
FTC challenges FDA's biosimilar naming proposal
October 31, 2015 1:42 AM UTC
The Federal Trade Commission raised concerns over FDA's draft guidance on biosimilar naming, and said attaching different suffixes to non-interchangeable biosimilars and their reference products could lead to reduced price competition for biologics.
In a comment filed in response to FDA's proposal, the FTC said distinct suffixes could lead physicians to believe biosimilars differ from their reference products in clinically meaningful ways. The FTC proposed using trade names, rather than suffixes, to distinguish between non-interchangeable biosimilars and reference biologics. ...